Although non-insulin-dependent diabetes mellitus (NIDDM) is associated with defects in insulin action, the molecular basis of this resistance is unknown. We studied fibroblasts from a markedly insulin-resistant patient with NIDDM but without acanthosis nigricans. Her fibroblasts were resistant to insulin when aaminoisobutyric acid uptake was measured. Fibroblasts from this patient demonstrated normal insulin-receptor content as measured by both insulinreceptor radioimmunoassay and by Scatchard analysis. However, when compared with nondiabetic control subjects, insulin-receptor kinase assays of wheat-germ-purified receptors prepared from her fibroblasts showed very low basal and no insulinstimulated tyrosine kinase activity. The insulin receptor was then removed from the wheat-germ fraction by monoclonal antibody affinity chromatography. This insulin-receptor-deficient fraction inhibited both basal and insulin-stimulated tyrosine kinase activity of highly purified insulin receptors. When the specificity of this inhibition was tested, less inhibition was seen with insulinlike growth factor l-receptor tyrosine kinase, and even less inhibition was seen with the proto-oncogene p60 csrc tyrosine kinase. Thus, these studies indicate that fibroblasts from an insulin-resistant patient with NIDDM produce a relatively specific glycoprotein inhibitor of insulin-receptor tyrosine kinase. Therefore, these studies raise the possibility that this inhibitor may play an important role in the insulin resistance seen in this patient. Diabetes 40:295-99,1991
N on-insulin-dependent diabetes mellitus (NIDDM) is associated with defects in both insulin secretion and insulin action (1) (2) (3) (4) . In most patients with NIDDM, the molecular basis of the insulin resistance is unknown. The cellular response to insulin is mediated through the insulin receptor (5) . The insulin receptor is a tetramer consisting of two identical extracellular a-subunits that bind the hormone and two identical transmembrane (3- subunits that have intracellular tyrosine kinase activity. When insulin binds to the a-subunit, the (3-subunit tyrosine kinase is activated and insulin action ensues (5) . A few patients with extreme insulin resistance and acanthosis nigricans have structural abnormalities in their insulin receptors (6) (7) (8) (9) (10) (11) , but in most patients with NIDDM, insulin-receptor function appears normal (12, 13) . In this study, we identified a patient with marked insulin resistance and NIDDM whose fibroblasts produce a factor that inhibits insulin-receptor kinase activity.
RESEARCH DESIGN AND METHODS
Fibroblasts from the patient were obtained by forearm skin biopsy and grown under standard conditions (14). Control fibroblasts from an age-and sex-matched individual were obtained from the National Institute of General Medical Sciences Human Genetic Cell Repository (Camden, NJ). Cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Cell Culture Facility, Univ. of California, San Francisco).
We purchased A14-125 l-labeled insulin (2200 Ci/mmol), [7- l-insulin receptor was radiolabeled and sodium dodecyl sulfate-polyacrylamide gel electrophoresis carried out as described previously (15) . Radioimmunoassay of insulin-receptor content was carried out as described previously (15) . Insulin binding to fibroblasts in suspension was carried out as described previously (16) , except that trypsin was omitted, and cells were treated with 1 mM EDTA and scraped from the dishes. In the binding experiments, 10 6 cells/ml were incubated with 125 l-insulin (100 pM) plus increasing concentrations of unlabeled insulin.
Insulin receptors and IGF-I receptors were semipurified from cell lines by wheat-germ agglutinin chromatography as described previously (17) . Insulin receptors were purified to homogeneity employing sequential insulin-receptor monoclonal antibody and wheat-germ agglutinin chromatography as described previously (18) .
Insulin-receptor autophosphorylation and insulin-receptor tyrosine kinase activity employing the artificial substrate poly(Glu-Tyr) were carried out as described previously (19) . In these studies, 2 ng of insulin receptor and IGF-I receptor and 0.2 ng p60 c -src were employed. Informed consent was obtained for the studies performed.
RESULTS
The patient was a nonobese 42-yr-old Hispanic woman with no diseases known to cause insulin resistance. She had asymptomatic diabetes mellitus with no evidence of acanthosis nigricans. Her oral glucose tolerance test (75 g glucose) revealed a basal glucose value of 7.5 mM with values of 10.5, 13.6, 16.2, and 12.9 mM at 30, 60, 120, and 180 min, respectively. The basal insulin concentration was 488 pM with values of 868, 1112, 1615, and 1364 pM at 30, 60, 120, and 180 min, respectively. To directly assess insulin resistance, she underwent a steady-state plasma glucose test (20) . Steady-state plasma glucose levels averaged 18 mM, indicating major insulin resistance (20) .
A skin biopsy was obtained, and fibroblasts were cultured. Several biological functions were studied in her fibroblasts and compared with age-and sex-matched control fibroblasts (Fig. 1) . When AIB uptake was studied, both the sensitivity and the responsiveness to insulin were blunted. When 2-deoxy-D-glucose uptake was studied, the sensitivity was blunted (data not shown).
Radioimmunoassay (15) subject revealed a value of 1.43 ng/fxg DNA. When compared with control fibroblasts, insulin binding by Scatchard analysis revealed normal binding parameters (Fig. 2 ). The insulin receptor was then purified to homogeneity by antibody-affinity and lectin-affinity chromatography, radiolabeled with t25 l-Bolton-Hunter reagent (Sigma), and electrophoresed under reducing conditions, and autoradiographs were obtained (Fig. 2) . When compared with receptors isolated from control fibroblasts, both the a-and 0-subunits were of normal size and abundance.
We next solubilized the patient's fibroblasts and prepared semipurified insulin receptors by wheat-germ agglutinin chromatography. In these preparations, both basal and insulin-stimulated tyrosine kinase activity was markedly diminished. This decrease in receptor kinase was seen both when receptor autophosphorylation was analyzed and when phosphorylation of the exogenous substrate poly(Glu-Tyr) was measured (Fig. 3) . Of major interest was the observation that, when the patient's receptor preparation was mixed with the control subject's receptor preparation, the insulin-stimulated tyrosine kinase activity was virtually abolished. The DNA sequence of the p-subunit tyrosine kinase ATP binding site and major triple autophosphorylation sites were amplified from genomic DNA (21) and analyzed, and the sequences were found to be normal.
To further analyze the structure of the patient's insulin receptors, we removed insulin receptors from her fibroblast wheat-germ preparation by monoclonal antibody-affinity chromatography and then tested the wheat-germ preparation. The purified insulin receptor from the patient had basal and insulin-stimulated tyrosine kinase activities that approached the activity of receptors purified from the nondiabetic control subject. The insulin-receptor-deficient wheat-germ preparation from the patient completely inhibited insulin-stimulated tyrosine kinase activity in a highly purified normal insulin-receptor preparation (obtained from HTC cells transfected with insulin-receptor cDNA and expressing high levels of human insulin receptor) (19; Fig. 4) . In contrast to the wheat-germ extract from the patient, a similarly prepared extract from a nondiabetic subject showed no inhibition; rather, it showed potentiation of receptor kinase.
Next, we tested this extract on the closely related IGF-I receptor and the more distantly related p60 c -src tyrosine kinase (22; Fig. 5 ). The extract inhibited insulin-stimulated tyrosine kinase activity at a concentration as low as 2.5 fil/ml, with a half-maximal inhibition at 5 uJ/ml. The extract was a less potent inhibitor of IGF-I-stimulated IGF-l-receptor ty- rosine kinase activity and an even less potent inhibitor of p60 c " src tyrosine kinase. The half-maximal inhibitions for the IGF-I receptor and p60 csrc were 8 |xl/ml and >10 |xl/ml, respectively, indicating the relative specificity of this inhibitor for the insulin receptor. Under the conditions of the kinase assay, the wheat-germ extract from the patient did not contain phosphotyrosine phosphatase activity.
DISCUSSION
These studies therefore indicate that an insulin-receptordeficient wheat-germ extract of fibroblasts from a patient with NIDDM contained a glycoprotein that specifically inhibited the tyrosine kinase activity of the insulin receptor.
Coughlin et al. (23) reported that Mullerian inhibiting substance is a glycoprotein that inhibits the tyrosine kinase activity of the epidermal growth factor receptor. In addition, Auberger et al. (24) reported that rat liver produces a glycoprotein that inhibits insulin-receptor kinase activity. This latter inhibitor had sequence homology to Mullerian inhibiting substance but was not detected in other rat tissues.
Our study demonstrates that fibroblasts from a patient with insulin resistance and NIDDM contain an inhibitor of insulinreceptor tyrosine kinase activity, which is relatively specific for the insulin receptor. Therefore, it is possible that the inhibitor produced by this patient's fibroblasts is a member of a larger family of related tyrosine kinase inhibitors. Inhibitors of the interleukin 2 action have also been reported, but these inhibitors apparently are not related to the aforementioned tyrosine kinase inhibitors (25) .
The patient described herein had marked insulin resistance without acanthosis nigricans, but unlike patients with extreme insulin resistance that are associated with acanthosis nigricans, she had neither circulating antibodies to the insulin receptor nor a receptor defect (6) (7) (8) (9) (10) (11) . Because this patient's fibroblasts produced a glycoprotein that inhibited insulin-receptor kinase, it is possible that this substance is present in other cells from this patient and may either contribute to or be the major cause of insulin resistance. If this is the case, it is unknown whether this patient has a rare form of NIDDM or whether she is the first reported individual of a distinct subset of patients with this disease. Therefore, further studies will be needed to characterize and identify this inhibitor and to determine its prevalence in patients with NIDDM.
